-+ 0.00%
-+ 0.00%
-+ 0.00%

Longeveron Appoints Stephen H. Willard CEO, Effective Feb. 11, Succeeding Than Powell

Benzinga·02/13/2026 21:31:09
Listen to the news

Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company's Board of Directors has appointed Stephen H. Willard as Chief Executive Officer, effective February 11, 2026. He succeeds Than Powell who served as interim CEO prior to the Board's appointment of Mr. Willard as permanent CEO. Mr. Powell will support the leadership transition and continue his work in the Company's on-going business development activities.